AbCellera Biologics (STU:8QQ) Debt-to-Equity : 0.07 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is AbCellera Biologics Debt-to-Equity?

AbCellera Biologics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €5.09 Mil. AbCellera Biologics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €62.63 Mil. AbCellera Biologics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €1,039.52 Mil. AbCellera Biologics's debt to equity for the quarter that ended in Mar. 2024 was 0.07.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for AbCellera Biologics's Debt-to-Equity or its related term are showing as below:

STU:8QQ' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.06 Max: 0.67
Current: 0.07

During the past 6 years, the highest Debt-to-Equity Ratio of AbCellera Biologics was 0.67. The lowest was 0.01. And the median was 0.06.

STU:8QQ's Debt-to-Equity is ranked better than
65.64% of 1068 companies
in the Biotechnology industry
Industry Median: 0.14 vs STU:8QQ: 0.07

AbCellera Biologics Debt-to-Equity Historical Data

The historical data trend for AbCellera Biologics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbCellera Biologics Debt-to-Equity Chart

AbCellera Biologics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.67

0.01

0.04

0.07

AbCellera Biologics Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.07	0.07	0.07	0.07	0.07

Competitive Comparison of AbCellera Biologics's Debt-to-Equity

For the Biotechnology subindustry, AbCellera Biologics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AbCellera Biologics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AbCellera Biologics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where AbCellera Biologics's Debt-to-Equity falls into.

AbCellera Biologics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

AbCellera Biologics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.647	+	65.311)	/	1056.676
	=	0.07

AbCellera Biologics's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.089	+	62.633)	/	1039.52
	=	0.07

AbCellera Biologics (STU:8QQ) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

AbCellera Biologics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of AbCellera Biologics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

AbCellera Biologics (STU:8QQ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AbCellera Biologics Inc (STU:8QQ) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

ABCL:USA

Address

2215 Yukon Street, Vancouver, BC, CAN, V5Y 0A1

Website

https://www.abcellera.com

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the most effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and leading pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

AbCellera Biologics (STU:8QQ) Headlines

No Headlines